Lannett Company, Inc. / UCB S.A. (Kremers Urban Pharmaceuticals Inc.)

Attention-Deficit/Hyperactivity Disorder (ADHD)

$5.7B Global methylphenidate market 2024 (USD)

Disease Overview

ADHD is a common neurodevelopmental disorder characterized by inattention, hyperactivity and impulsivity, typically diagnosed in childhood and frequently persisting into adulthood. CDC data indicate roughly 7 million US children (11.4% of those aged 3-17) had ever been diagnosed with ADHD as of 2022, and stimulants such as methylphenidate remain first-line pharmacotherapy.

Competitive Landscape

The US ADHD stimulant market is anchored by branded extended-release methylphenidate franchises — Concerta (Janssen), Ritalin LA (Novartis), Focalin XR (Novartis), Quillivant XR/Cotempla XR-ODT (Tris) — alongside amphetamine-class products Adderall XR, Vyvanse (Takeda) and Mydayis. Generic methylphenidate ER and amphetamine ER make up the bulk of dispensed prescriptions, with the methylphenidate market alone valued at ~$5.7B globally in 2024 (verifiedmarketreports.com). Kremers Urban's AB-rated generic methylphenidate ER, modeled on Concerta, was a flagship asset for Lannett at deal close — but the FDA had already downgraded it to a BX rating, blocking automatic substitution and turning a planned cash cow into a contested franchise (fiercepharma reporting on the deal close, ucb.com IR materials). Lannett financed the $1.23B Kremers Urban acquisition with a $1.035B secured credit facility plus $250M senior unsecured notes, betting that AB-rating restoration plus 18 marketed generics and 11 pending ANDAs would be accretive to FY16-17 EPS by 20-25% (prnewswire.com 2015-11-30). The deal closed November 27, 2015, and was the largest in Lannett's history; subsequent deterioration in generic pricing and the methylphenidate ER rating dispute later forced major impairments.